A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Actavis Inc.
ClinicalTrials.gov Identifier:
NCT00865436
First received: March 18, 2009
Last updated: August 13, 2010
Last verified: August 2010

March 18, 2009
August 13, 2010
April 2004
April 2004   (final data collection date for primary outcome measure)
Rate and Extend of Absorption [ Time Frame: 36 hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00865436 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions
A Relative Bioavailability Study of 5 mg Glyburide/500 mg Metformin HCl Tablets Under Fasting Conditions

The purpose of this study is compare the relative bioavailability of 5 mg Glyburide/500 mg Metformin Hydrochloride Tablets by Alpharma with that of 5 mg/500 mg CLUCOVANCE® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 5 mg/500 mg tablet) in healthy adult volunteers administered under fasting conditions.

Study Type: Interventional Study Design: Randomized, single dose, two-way crossover study under fasting conditions

Official Title: A Relative Bioavailability Study of 5 mg Glyburide/500 mg Metformin HCl Tablets Under Fasting Conditions

Further study details as provided by Actavis Elizabeth LLC:

Primary Outcome Measures:

Rate and Extend of Absorption

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Healthy
  • Drug: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
    A: Experimental Subjects received Alpharma formulated products under fasting conditions
    Other Names:
    • Glyburide
    • Metformin
  • Drug: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
    B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
    Other Names:
    • Glyburide
    • Metformin
  • Experimental: A
    Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, single dose
    Intervention: Drug: Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg
  • Active Comparator: B
    CLUCOVANCE® 5 mg/500 mg Tablets, single dose
    Intervention: Drug: CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
April 2004
April 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Screening Demographics: All volunteers selected for this study will be healthy men or women 18 years of age or older at the time of dosing. The weight range will not exceed ± 20% for height and body frame as per Desirable Weights for Adults -1983 Metropolitan Height and Weight Table.
  2. Screening Procedures: Each volunteer will complete the screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.

    Screening will include general observations, physical examination, demographics, medical and medication history, an electrocardiogram, sitting blood pressure and heart rate, respiratory rate and temperature. -The physical examination will include, but may not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems.

    The screening clinical laboratory procedures will include:

    • HEMATOLOGY: hematocrit, hemoglobin, WBC count with differential; RBC count, platelet count;
    • CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total bilirubin, total protein, and alkaline phosphatase;
    • HIV antibody and hepatitis B surface antigen screens;
    • URINALYSIS: by dipstick, microscopic examination if dipstick positive; and.
    • URINE DRUG SCREEN: ethyl alcohol, amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolites, opiates and phencyclidine.
    • SERUM PREGNANCY SCREEN (female volunteers only)
  3. If female and:

    • of childbearing potential, is practicing an acceptable barrier method of birth control for the duration of the study as judged by the investigator(s), such as condoms, sponge, foams, jellies, diaphragm; intrauterine device (IUD), or abstinence; or
    • is postmenopausal for at least I year; or
    • is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).

Exclusion Criteria:

  1. Volunteers with a recent history of drug or alcohol addiction or abuse.
  2. Volunteers with the presence of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the medical investigator).
  3. Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
  4. Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen.
  5. Volunteers demonstrating a positive drug abuse screen when screened for this study.
  6. Female volunteers demonstrating a positive pregnancy screen.
  7. Female volunteers who are currently breastfeeding.
  8. Volunteers with a history of allergic response(s) to glyburide, metformin or related drugs.
  9. Volunteers with a history of clinically significant allergies including drug allergies.
  10. Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the medical investigator).
  11. Volunteers who currently use tobacco products.
  12. Volunteers who have taken any drug known to induce or inhibit hepatic• drug metabolism in the 28 days prior to Period I dosing.
  13. Volunteers who report donating greater than 150 mL of blood within 28 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
  14. Volunteers who have donated plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.
  15. Volunteers who report receiving any investigational drug within 28 days prior to Period I dosing.
  16. Volunteers who report taking any systemic prescription medication in the 14 days prior to Period I dosing.
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00865436
R04-0248
No
Meena Venugopal, Director, Clinical R&D, Actavis Inc
Actavis Inc.
Not Provided
Principal Investigator: James D. Carlson,, Pharm.D, PRACS Institute, Ltd.
Actavis Inc.
August 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP